Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology ...Middle East

This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform, similar to the preclinical stage KAT6 inhibitor (MEN2312) licensed a year ago and which advanced rapidly into the clinical phase. Under the agreement,...

Read More Details
Finally We wish PressBee provided you with enough information of ( Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology )

Also on site :

• Mossad thanks CIA for help with Operation Rising Lion
• What to Know About the Investigation Into Influencer Gloria Zamora’s Death
• Egypt vows no power cuts this summer, cites gas supply boost